Clinical trial
GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer
NCT00068588 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00068588 |
|---|---|
| Title | GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer |
| Official title | A Phase 2 Study of GTI-2040 (NSC 722929) in Combination With Capecitabine in Metastatic Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | GTI-2040, capecitabine |
| Enrollment | 24 |
| Start date | Oct 1, 2003 |
| Primary completion | Mar 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | Sep 11, 2003 |
| Last update posted | Oct 31, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: